✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist

Becton, Dickinson and Company (NYSE:BDX) is included among the Top 10 Income Stocks with the Highest Upside Potential.

On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe lower utilization across the healthcare sector. As a result, BofA is taking a more cautious approach to 2027 estimates for medtech companies, particularly since current valuations already reflect some utilization-related risks.

The analyst also expects inflation to remain a greater headwind in 2027, which could limit margin expansion across the medtech industry. Based on those assumptions, BofA reduced its 2027 estimates for several large-cap companies in its coverage universe that have exposure to both utilization trends and inflation pressures.

Becton, Dickinson and Company is a global medical technology company. It develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its products are used by healthcare institutions, physicians, life science researchers, clinical laboratories, and other healthcare professionals.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and Billionaire Larry Robbins’ 10 Dividend Stock Picks

Follow Insider Monkey on Google News.